PHAR Pharming Group N.V.
$11.21▲ +3.75%
Healthcare
Other
After hours
$11.21▲ +0.00%
Sep 11, 7:30 PM ET
Volume 38.5K
Avg Volume (10D) 12.8K
Key Metrics & Fundamentals
Market Cap
$793.42M
P/E Ratio
80.1
Div Yield
–%
52W Range
9.62 - 21.34
% vs 50 MA
-7.59%
% vs 200 MA
-25.16%
RSI-14
45.3
MACD Histogram
-0.0200
Beta (1Y vs SPY)
0.99
Free Cash Flow
-$9.74M
Gross Rev
$90.21M
Gross Profit
$75.67M
EBITDA
$8.75M
COGS
$14.55M
Operating Exp
$75.78M
Operating Income
-$111,000
EBIT
-$111,000
Pretax Income
$3.04M
Net Income
$1.64M
Price & Volume History
Loading chart…
Recent News
FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
GlobeNewswire · Sep 11, 2026 6:00 PM
Pharming Group to participate in September investor conferences
GlobeNewswire · Sep 9, 2026 6:00 AM
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
GlobeNewswire · Aug 13, 2026 5:00 AM
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
GlobeNewswire · Aug 4, 2026 6:00 AM
Pharming Group (ENXTAM:PHARM) Could Be 63% Undervalued After Guidance Cut And Half Year Results
Simply Wall St. · Aug 3, 2026 12:15 AM
Pharming Group (PHGUF) (Q2 2026) Earnings Call Highlights: Joenja Surges 40% as Ruconest Faces ...
GuruFocus.com · Jul 30, 2026 7:04 PM
Pharming Group Q2 Earnings Call Highlights
MarketBeat · Jul 30, 2026 1:04 PM
Pharming Group's Q2 Earnings, Revenue Fall; 2026 Revenue Outlook Updated
MT Newswires · Jul 30, 2026 8:02 AM
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
GlobeNewswire · Jul 30, 2026 5:00 AM
Earnings To Watch: Pharming Group (XAMS:PHARM) Q2 2026 -- GF Value Sees 36% Upside
GuruFocus.com · Jul 29, 2026 2:00 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See PHAR's money flow as a full page
Social Sentiment
No Reddit posts found for PHAR.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.